StockTipsArenaBeta

BUY Dr. Reddy's Laboratories Limited — CLSA

BUYDr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories share price target & all analyst calls

byCLSAHorizon: NA (inferred 1 year)23 Jul 2026via CNBC Awaaz.

Entry₹1,154.7Inferred
Target₹1,240
Total upside +7.39% (call closed)
Stop lossNot given
Exit₹1,24029 Sept 2026, 12:09 pm
Target hit+7.39%0.00%upside left
Follow CLSA for new calls(100% target hit, 24 closed calls)Get alertsWatch DRREDDY for new buy/sell callsGet alertsSee 19 active Long-term calls on DRREDDYSee 274 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 29 Sept 2026
11 supporting7 neutral7 opposing
Supports the BUY call (11)

Hikma signs exclusive licensing and distribution agreement with Dr. Reddy’s Laboratories for Nicotinell across MENA

NewsGoogle News·28 Sept · today

(opens in new tab)

4 advisors have active short-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · adjacent horizon·28 Sept · today

7 other SEBI-registered advisors have active long-term BUY calls on this stock, with 2 issued in the last 14 days

Advisor consensus · same horizon·29 Sept · today

Dr Reddy's Laboratories stock gains as Q1 profit falls

NewsGoogle News·23 Sept · 5d ago

(opens in new tab)

Dr. Reddy's Laboratories has entered into an exclusive distribution and marketing agreement with Takeda Biopharmaceuticals India for Qdenga®, a dengue vaccine, in the private market in India. The agre

BSE · Company Update·18 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (7)

Nothing found in this tip’s window yet.

Weighs against the BUY call (7)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NewsGoogle News·25 Sept · 4d ago

(opens in new tab)

Dr. Reddy's faces securities fraud probe after Q1 earnings hit by semaglutide batch issues.

NewsGoogle News·24 Sept · 5d ago

(opens in new tab)

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NewsGoogle News·10 Sept · 3w ago

(opens in new tab)

5 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·23 Jul · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Dr. Reddy's Laboratories

All analyst calls on Dr. Reddy's Laboratories

More from CLSA

Every call and its outcome